A MULTICENTER, RANDOMIZED CLINICAL TRAIL EVALUATE EFFECTIVENESS AND SECURITY OF CAPECITABINE OR ENDOCRINOTHERAPY AS A MAINTENANCE THERAPY REGIMEN AFTER THE 1ST-LINE CHEMOTHERAPY WITH CAPECITABINE COMBINE REGIMEN IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE METASTATIC BREAST CANCER(OVERSTEP):